TPWA
MDGL icon

Twin Peaks Wealth Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9
Closed -$4.71K – 1395
2026
Q1 		$4.71K Buy
+9
New +$4.3K ﹤0.01% 1417
2025
Q3 		– Sell
-5
Closed -$1.79K – 1321
2025
Q2 		$1.79K Buy
+5
New +$1.49K ﹤0.01% 1652

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Twin Peaks Wealth Advisors's MDGL Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 9 shares — an estimated $4.71K sold.

Twin Peaks Wealth Advisors first reported a position in MDGL in Q2 2025 and held it in 2 quarters. The position peaked at $4.71K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 9 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $4.71K.
  • Twin Peaks Wealth Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Madrigal Pharmaceuticals position peaked at $4.71K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.